Trump's investment accounts saw thousands of trades totaling hundreds of millions of dollars between January and March. This feverish activ...

Bio Medica Laboratories' shares are set to list on the NSE SME platform amidst weak grey market sentiment, with the IPO currently trading a...

ValueQuest's Sameer Shah champions a private equity approach to public markets. He focuses on deep research and conviction in identifying t...

Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and...

Leading analyst Devarsh Vakil suggests Indian markets offer compelling buying opportunities now, with valuations correcting to attractive l...

Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...

Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Market expert Sudip Bandyopadhyay warns Indian markets face significant risks. High oil prices and a potential monsoon deficit are major co...

RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...

Dr Reddy's Laboratories has achieved a significant milestone. Health Canada has approved its generic semaglutide injection. This makes Dr R...

Dr Reddy's Laboratories has secured market authorization from Health Canada for its generic semaglutide injection. This marks a significant...

AU Small Finance Bank reported a robust 65% year-on-year surge in net profit for the March quarter, reaching Rs 832 crore. The lender also ...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

Indian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...

A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...